Kidswell Bio Corporation Logo

Kidswell Bio Corporation

Biopharmaceutical firm focused on R&D of therapeutics for pediatric healthcare.

4584 | T

Overview

Corporate Details

ISIN(s):
JP3386460004
LEI:
Country:
Japan
Address:
中央区新川一丁目2番12号

Description

Kidswell Bio Corporation is a biopharmaceutical company engaged in the research and development of innovative therapeutics, with a particular focus on pediatric healthcare. The company's operations are centered on three main pillars: the Biosimilars business, which leverages expertise in cell line development and CMC; the Cell Therapy business, which pursues regenerative medicine through its subsidiary S-Quatre Corporation for conditions such as cerebral palsy; and the New Biologics business, focused on developing novel drugs. The company aims to create a comprehensive healthcare system for children and their families through its advanced R&D pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-08-14 08:15
四半期報告書-第21期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese 202.6 KB
2020-07-22 09:05
訂正有価証券報告書-第20期(平成31年4月1日-令和2年3月31日)
Japanese 721.6 KB
2020-07-17 08:06
有価証券報告書-第20期(平成31年4月1日-令和2年3月31日)
Japanese 1.2 MB
2020-02-05 07:14
四半期報告書-第20期第3四半期(令和1年10月1日-令和1年12月31日)
Japanese 176.9 KB
2019-11-13 02:18
四半期報告書-第20期第2四半期(2019/07/01-2019/09/30)
Japanese 174.7 KB
2019-08-07 02:51
四半期報告書-第20期第1四半期(2019/04/01-2019/06/30)
Japanese 134.0 KB
2019-06-28 05:03
有価証券報告書-第19期(平成30年4月1日-平成31年3月31日)
Japanese 1.2 MB
2019-02-07 07:09
四半期報告書-第19期第3四半期(2018/10/01-2018/12/31)
Japanese 153.6 KB
2018-11-07 01:04
四半期報告書-第19期第2四半期(2018/07/01-2018/09/30)
Japanese 149.1 KB
2018-08-07 02:27
四半期報告書-第19期第1四半期(2018/04/01-2018/06/30)
Japanese 154.7 KB
2018-06-29 02:44
有価証券報告書-第18期(平成29年4月1日-平成30年3月31日)
Japanese 1.4 MB
2018-02-08 01:29
四半期報告書-第18期第3四半期(2017/10/01-2017/12/31)
Japanese 125.3 KB
2017-11-09 02:43
四半期報告書-第18期第2四半期(2017/07/01-2017/09/30)
Japanese 148.4 KB
2017-08-10 02:22
四半期報告書-第18期第1四半期(2017/04/01-2017/06/30)
Japanese 123.7 KB
2017-06-29 03:00
有価証券報告書-第17期(2016/04/01-2017/03/31)
Japanese 1.0 MB

Automate Your Workflow. Get a real-time feed of all Kidswell Bio Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kidswell Bio Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kidswell Bio Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.